Meaningful tumor reduction in clinical trial patients with advanced CSCC1,2

Response in patients with mCSCC or laCSCC who were not candidates for curative surgery or curative radiation1

Patient responses

These are examples from the 31% of patients who had a PR in the combined analysis of patients who received LIBTAYO 3 mg/kg Q2W in Study 1540.1
Individual patient responses may vary.

Supra-
clavicular
Lesion
History2
  • Metastatic CSCC
  • Supraclavicular lesion with distant metastasis
  • 85-year-old male
Supra-clavicular lesion, screening image, after 8 weeks, after 56 weeks
Right
Auricular
Lesion
History2
  • Locally advanced CSCC
  • Clinical judgment was that tumor would be unlikely to respond to RT
  • 57-year-old male
Right auricular lesion, screening image, after 24 weeks, after 88 weeks
Right
Cranial
Lesion
Right
Auricular
Lesion
History2
  • Locally advanced CSCC
  • MDT deemed that radiotherapy was contraindicated
  • 70-year-old male
Right cranial lesion and right auricular lesion, screening image, after 16 weeks, after 96 weeks Auricular lesion Right cranial lesion and right auricular lesion, screening image, after 16 weeks, after 96 weeks
These are examples from the 15% of patients who had a CR in the combined analysis of patients who received LIBTAYO 3 mg/kg Q2W in Study 1540.1
Left
Auricular
Lesion
History2
  • Locally advanced CSCC
  • Anterior auricular lesion that would have required an auriculectomy
  • 65-year-old male
Left auricular lesion, screening image, after 8 weeks, after 64 weeks
Peri-
clavicular
Lesion
History2
  • Distant metastatic CSCC
  • Subcutaneous metastases
  • Cancer spread to the lymph nodes
  • 66-year-old male
Peri-clavicular lesion, screening image, after 24 weeks, after 64 weeks
LIBTAYO Patient Cases

The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.1

  • CR=complete response; CSCC=cutaneous squamous cell carcinoma; ICR=independent central review; MDT=multidisciplinary team; PR=partial response; Q2W=every 2 weeks; RECIST=Response Evaluation Criteria in Solid Tumors; RT=radiation therapy; WHO=World Health Organization.


Please see full Prescribing Information.
This video reviews the clinical trial designs, efficacy results, and safety data of LIBTAYO. It also includes a brief case study discussion of a 57-year-old patient with locally advanced CSCC who was not a candidate for curative surgery or curative radiation, and was enrolled in the LIBTAYO clinical trial for advanced CSCC.
Chapter 1 Dr Chandra's and Dr Moody's introductions
Chapter 2 Overview of LIBTAYO
Chapter 3 LIBTAYO clinical trial designs for Study 1423 and Study 1540
Chapter 4 Efficacy results of LIBTAYO in advanced CSCC (time to response, objective response rate, duration of response)
Chapter 5 Safety profile of LIBTAYO in advanced CSCC
Chapter 6 Patient case study (57-year-old male with locally advanced CSCC)
Chapter 7 Important Safety Information
Chapter 8 References

References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron PharmaceuticaIs, Inc., and sanofi-aventis U.S. LLC. 2. Data on file. Regeneron Pharmaceuticals, Inc.